Biocon receives Establishment Inspection Report from FDA for Bengaluru facilities

Apr 16, 2020

On 16 April 2020, Biocon announced it had received an Establishment Inspection Report (EIR) from the FDA for two biologics facilities in Bengaluru. Biocon expects that this EIR will allow for the filing of marketing authorisation applications for biosimilar products in several global markets.

Print Page Mail Article